A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine for Patients Diagnosed with Mild to Moderate COVID-19 Infections

Table 3

The results of the copy number of the virus of Control and treatment groups were analyzed in subjects with mild severity and total subjects evaluated using qRT-PCR on treatment days 1, 3, and 7.

Period of treatment	Control	A	B	C	D	E	value
Copy number of virus in subjects with mild severity
Day 1	193.2 (14.1–48,113.7)	67.0 (11.9–4,531.4)	73.2 (11.9–2,945.8)	173.3 (12.4–5,116.0)	828.8 (11.8–370,523.6)	588.4 (11.0–11,877.6)
Day 3	49.9.0 (0.0–15,085.1)	0.0 (0.0–120.6)	0.0 (0.0–172.8)	0.0 (0.0–617.9)	0.0 (0.0–1,341.9)	0.0 (0.0–1,547.8)
Day 7	19.8 (0.0–1,445.6)	0.0 (0.0–3,191.4)	0.0 (0.0–66.7)	0.0 (0.0–100.7)	0.0 (0.0–114.8)	0.0 (0.0–148.3)
Copy number of virus in total subjects
Day 1	193.2 (14.1–48,113.7)	67.0 (11.9–4,531.4)	73.2 (11.9–2,945.8)	183.6 (12.4–5,116.0)	854.8 (11.8–370,523.6)	670.0 (11.0–11,877.6)	0.001
Day 3	45.4 (0.0–15,085.1)	0.0 (0.0–120.6)	0.0 (0.0–172.8)	0.0 (0.0–617.9)	0.0 (0.0–2,900.6)	0.0 (0.0–1,547.8)	0.012
Day 7	19.8 (0.0–1,445.6)	0.0 (0.0–3,191.4)	0.0 (0.0–66.7)	0.0 (0.0–100.7)	0.0 (0.0–278.0)	0.0 (0.0–148.3)	0.039

Control group: 1 × 500 mg azithromycin per day; Group A: 2 × 200/50 mg lopinavir/ritonavir + 1 × 500 mg azithromycin per day; Group B: 2 × 200/50 mg lopinavir/ritonavir + 2 × 100 mg doxycycline per day; Group C: 2 × 100 mg hydroxychloroquine + 1 × 500 mg azithromycin per day; Group D: 2 × 400/100 mg lopinavir/ritonavir + 1 × 500 mg azithromycin per day; Group E: 2 × 400/100 mg lopinavir/ritonavir + 2 × 100 mg doxycycline per day.